Information  X 
Enter a valid email address

Open Orphan PLC Ord 0.1P (ORPH)

Related News

06-Jan-2021 09:43 AM

Open Orphan's Venn Life Sciences renews contract with global pharmaceutical client

Specialist pharmaceutical services clinical research organisation Open Orphan has renewed its Venn Life Sciences team's contract with a major top three global pharmaceutical client to the end of December 2021. The Venn team in the Breda office in t
30-Sep-2020 09:00 AM

Open Orphan losses deepen; targets operating profitability by fourth quarter

Pharmaceutical services group Open Orphan posted a deeper first-half loss owing to costs following its acquisition of hVIVO in January. Pre-tax losses for the six months through June amounted to £6.8 million, compared to losses of £1.1 millio
24-Jun-2020 02:15 PM

Open Orphan books annual loss as expenses weigh

Pharmaceutical services company Open Orphan booked a full-year loss and said it was looking to sell non-core assets. Pre-tax losses for the year through December amounted to €6.6m, compared to losses of €1.7m for the period running between 18 J
26-May-2020 08:50 AM

Broker Forecast - finnCap issues a broker note on

finnCap today initiates coverage of (LON:ORPH) with a corporate investment rating and price target of 19p. Story provided by Broker Forecasts data provided by
27-Feb-2020 07:07 AM

Open Orphan names new CFO

Specialist CRO pharmaceutical services company has appointed a chief financial officer to the board. Leo Toole joins the firm having held senior positions at Procter and Gamble, ResMed and Sublimity Therapeutics. Through positions in multinational com
23-Jan-2020 07:30 AM

Open Orphan provides placing update

Pharmaceutical services company, Open Orphan, has confirmed that it is currently undertaking meetings with investors in connection with its proposed placing of £5 million. The company, which has a focus on orphan drugs, hopes to complete the placi
06-Jan-2020 08:27 AM

Open Orphan signs three-year consultancy deal with German pharma giant

Pharmaceutical consultancy Open Orphan has signed a new three-year contract with a tier-one German pharmaceutical company. The contract, with one of Europe's top research-driven pharmaceutical companies, guarantees significant annual revenue with wo
Top categories
Company finder

a d v e r t i s e m e n t